Global Breast Cancer Drug Market: Focus on Development of Novel Therapeutics Representing an Innovative Occasion for Market Expansion

Global Breast Cancer Drug Market

Breast cancer drugs are the therapeutics utilized in the treatment of cancer occurring in the breasts of patients. These drugs are utilized in different treatment methods ranging from chemotherapy, targeted therapy, immunotherapy, hormone therapy among various other modes. These drugs provide an effective mode of reducing the prevalence of cancer cells in the breast area

Access Full Report at https://www.databridgemarketresearch.com/reports/global-breast-cancer-drug-market

Breast cancer drug market is growing due to increasing in prevalence rate of breast cancer drug worldwide, early detection of breast cancer; the effects of these factors are mentioned below:

  • Increasing in prevalence rate of breast cancer: The demand for effective treatment methods and drugs is being driven by the fact that the population suffering from breast cancer is rising rapidly. This increased prevalence of the population suffering from breast cancer is one of the major factors giving rise to greater adoption of drugs designed for breast cancer
  • Early detection of breast cancer: Another valuable factor that is giving rise to high adoption for these drugs is the prevalence of various screening programs along with the awareness amongst the individuals regarding self-check exams. These initiatives have resulted in higher detection rate of patient suffering from cancer at a very early stage, this result in the rapid improvements chances of survival and recovery of patients from treatment process. The detection of patients at an early stage also gives rise to counter the tumors head-on as the dosage of drugs can be enhanced to inhibit the growth of tumor

Strategic acquisitions and product innovations presented by various market players:

  • In May 2019, Novartis announced that they had received U.S. FDA approval for “Piqray”, designed for treatment of postmenopausal women and men who are hormone receptor positive, human epidermal growth factor receptor-2 negative, PIK3CA-mutated, advanced or metastatic breast cancer. Pigray is designed to be used in combination with “fulvestrant”, and has been approved based on the Phase III trial conducted by Novartis. This approval is evident of the focus of U.S. FDA and Novartis on developing effective therapeutics that are currently clinically unmet
  • In April 2019, Emcure Pharma announced the availability of a generic version of Eisai Pharma’s Eribulin, designed for treatment of breast cancer. The generic version will be available at a significantly lower cost at around forty percent lower than the original. The product will be produced in Mumbai, India. This availability will significantly improve affordability of effective therapeutics for patients suffering from breast cancer, which is experiencing a rise in the region

The market is segmented on the basis of mechanism of cation type as HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, CDK 4/6 inhibitors, hormonal receptor; type is categorized into DCIS, IDC, tubular carcinoma of the breast, medullary carcinoma of the breast, mucinous carcinoma of the breast, papillary carcinoma of the breast, cribriform carcinoma of the breast, ILC, inflammatory breast cancer, LCIS, male breast cancer, molecular subtypes of breast cancer, paget’s disease of the nipple, phyllodes tumors of the breast, metastatic breast cancer, others; stage as T:primary tumor size, N:lymp node involvement, M:cancer spread beyond the breast & lymph nodes; drug type as herceptin hylecta, atezolizumab, talazoparib, ribociclib, abemaciclib, neratinib, palbociclib, others; therapy type as medication, chemotherapy, targeted therapy, surgery; route of administration as oral, injectable; end-users as hospitals, homecare, specialty clinics, others.

“According to Data Bridge Market Research, global breast cancer drug market is expected be growing with a healthy CAGR of 11.1% during the forecast period of 2019 to 2026”

Some of the major players operating in market are AbbVie Inc, AstraZeneca Plc, Celgene Corporation, Merck & Co., Inc., Celldex Therapeutics, MacroGenics, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Sanofi S.A among others.

The focus of various pharmaceutical manufacturers in the market is on the development of novel therapeutic systems that can be effective in the treatment of cancer. Various pharmaceutical manufacturers are dealing in innovative R&D activities for the production of targeted therapeutics which can reduce the risk of cancer appearing again. These innovations and advancements are set to expand the reach of the market as major pharmaceutical companies will focus on getting their drugs commercialized as efficiently as possible.